Aim immunotech stock. 33% from the current AIM share price of $0.

Aim immunotech stock (AIM) with a description, list of executives, contact details and other key facts. Common Stock (AIM) stock quotes, trades, and more. Date Ratio; Jun. 12,102,649 for using Ampligen® to treat endometriosis, a condition affecting nearly 10% of reproductive-age women. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted key clinical, regulatory and corporate milestones AIM ImmunoTech 2117 SW Highway 484 Ocala, FL 34473 Phone: 352-448-7797 Fax: 352-480-4620 Email: info@AIMimmuno. What is Aim Immunotech's Beta? AIM has a beta of 1. AIM’s stock price has declined by more than 99%. represents a pivotal moment that could significantly impact the company's valuation and stock performance. chart to track its stock's price action. Research AIM ImmunoTech's (NYSEAM:AIM) stock key valuation metrics while comparing it with its industry peers & market side by side. 91% and reach $ 0. Ampligen, an RNA product candidate designed to modulate the AIM ImmunoTech Stock Performance. The patent covers compositions and methods using AIM's double-stranded RNA products for treating endometriosis, including recurrent cases. Get the latest AIM ImmunoTech Inc (AIM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. (AIM) Add to watchlist. 07% from the current stock price of 0. 26% growth. 00K with 43. 67% compared to the previous year. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente OCALA, Fla. AIM ImmunoTech has filed its definitive proxy statement for the 2024 Annual Meeting, warning shareholders about an activist group's attempt to take control of the Board. © AIM ImmunoTech Inc. Please see the "Historical Prices" tab for adjusted price values. AIM 1W Final Edit Wave (4) (A)(B)(C) Corrective Test AIM ImmunoTech, Inc. 00K, up 19. Aim Immunotech (NYSEMKT: AIM) is owned by 14. The trial focused on the treatment AIM ImmunoTech Inc. Select a stock. See many years of revenue, expenses and profits or losses. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,653,036 shares of common stock in a registered direct offering at a purchase price of $0. 00K USD in the quarter ending September 30, 2024, a decrease of -23. (AIM) growth grade and underlying metrics. (NYSE American: AIM) has been granted U. stock price gained 8. As previously announced, the Company will host a conference call and webcast today, Tuesday, April 2, 2024, at 8:30 AM ET (details below). 30, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. See each day's opening price, high, low, close, volume, and change %. com AIM ImmunoTech 2117 SW Highway 484 Ocala, FL 34473 Phone: 352-448-7797 Fax: 352-480-4620 Email: info@AIMimmuno. (AIM) latest earnings report: revenue, EPS, surprise, history, news and analysis. 28M shares of common stock for holders SA News Thu, Jul. Its products include Alferon N Injection and Ampligen. com AIM ImmunoTech exhorte les actionnaires à voter 'POUR' tous les quatre membres actuels du conseil d'administration lors de la prochaine Assemblée Générale Annuelle de 2024. 19. Get AIM ImmunoTech Inc (AIM:NYSE American) real-time stock quotes, news, price and financial information from CNBC. Securities and Exchange Commission in connection with its upcoming 2024 Annual Meeting of Stockholders, scheduled for December 17, 2024. 17% price volatility over the last 30 days. Detailed annual and quarterly income statement for AIM ImmunoTech (LON: 0A4Y). , Dec. AIM ImmunoTech Inc Stock forecast & analyst price target predictions, earnings, revenue ,EPS predictions, upgrades and downgrades. 00 and a high estimate of 4. Governance Documents; Board of Directors; Committee Composition; Stockholder Meeting; AIM ImmunoTech 2117 SW Highway 484 Ocala, FL Detailed statistics for AIM ImmunoTech Inc. – AIM ImmunoTech Inc. 62, which is 195. Dashboard Portfolios Watchlist Community Discover Screener. 25% based on their 12-month stock forecasts. An announcement from AIM ImmunoTech ( ) is now available. (NYSE American: AIM) has released a new CEO Corner segment on its website. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. Carter is the largest individual Aim Immunotech shareholder, owning 2. Make informed investments with Nasdaq. (NYSE American: AIM) (the “Company”) today announced that the Company has filed its definitive proxy statement with the U. See the latest AIM ImmunoTech Inc stock price (AIM:XASE), related news, valuation, dividends and more to help you make your investing decisions. (AIM) currently has an average brokerage recommendation (ABR) of 1. 86%: 50-Day Moving Average : 0 The AIM ImmunoTech Inc. Includes date and ratio. The company highlights serious concerns about the nominees: Robert Chioini was previously fired for mismanagement, Todd Deutsch has connections to individuals involved in AIM ImmunoTech Announces Cash Conservation Plan Independent Board Members to Receive 100% of Director Compensation in AIM Stock Follows Previously Disclosed Amendments to Executive Employment Agreements to Reduce Cash Component of Compensation for CE 11-27 Discover AIM ImmunoTech's earnings and revenue growth rates, AIM ImmunoTech Inc. – Continued execution across Ampligen® (rintatolimod) clinical Get the latest updates on AIM ImmunoTech Inc. ; The AIM ImmunoTech 52-week high stock price is 0. 220019 per share by February 18, 2025. 2194 USD. AIM Stock Data Market Cap 12. AIM updated stock price target summary. 64% year-over-year. Common Stock (AIM) at Nasdaq. The last closing price for AIM ImmunoTech was $0. Institutions Ownership 14. Annual report of employee stock purchase, savings and similar plans : Jun 21, 2013: 15-12G: Securities registration termination : Jun 19, 2013: S-8 POS: According to analysts, AIM ImmunoTech's stock has a predicted upside of 1,186. 217. . 57%. The 2 analysts with 12-month price forecasts for AIM ImmunoTech stock have an average target of 2. Stock - Stock Price, Institutional Ownership, Shareholders (NYSEAM) AIM ImmunoTech Inc. Common Stock (AIM) including 10-K and 10-Q forms at Nasdaq. 57% Aim Immunotech insiders, and 73. The Kellner Group, AIM Immunotech's largest stockholder, urges shareholders to vote using the GOLD proxy card to elect new board members, citing serious concerns about the incumbent board's conduct. See AIM ImmunoTech Inc. (AIM) price, historical values, financial information, New York Stock Exchange • NLS real time price • CURRENCY IN USD • Biotechnology & Medical Research. , April 02, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum See AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted key clinical, regulatory and corporate milestones AIM ImmunoTech (AIM) highlighted key clinical, regulatory and corporate milestones achieved over 2024 and outlined its expected upcoming milestones. com AIM ImmunoTech (AIM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. is a good stock to buy or sell based on recent news as well as its key financial metrics. stock information by Barron's. AIM ImmunoTech Future Growth. 22: 200 Find the latest AIM ImmunoTech Inc. Equels, Chief Executive Officer of AIM will AIM ImmunoTech reports improved Q2 2024 financials, with reduced losses and R&D expenses. The announcement by AIM ImmunoTech Inc. Create real-time notifications to follow any changes in the live stock price. 200 to a day high of $0. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. 214. Subscribe for free today! Executive Vice Chairman recently bought US$50k worth of stock Jan 05. Key 2024 achievements include: commencement of the DURIPANC Phase 1b/2 study combining Detailed annual and quarterly income statement for AIM ImmunoTech (AIM). , an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, About AIM ImmunoTech Inc. 8 days ago - AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - GlobeNewsWire 8 days ago - AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting - Business Wire 9 days ago - AIM ImmunoTech Reminds Shareholders to Vote “FOR” Convert AIM ImmunoTech Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. View daily, weekly or monthly format back to when AIM ImmunoTech Inc. The Delaware AIM ImmunoTech had revenue of $50. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AIM ImmunoTech Inc. Securities and Exchange Commission in AIM ImmunoTech Inc. (AIM). apple; wise; Select a currency. 16 - $0. (LON: AIM ImmunoTech Inc. (AIM) stock price, news, historical charts, analyst ratings and financial information from WSJ. The activist group, which includes individuals with ties to securities law felons, aims AIM News. 08%. Rodino III have decided to forego their entitled cash bonuses for 2024. 22. Get the latest AIM ImmunoTech Inc AIM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,653,036 shares of common stock in a registered View today's AIM ImmunoTech Inc stock price and latest AIM news and analysis. com Interactive stock price chart for AIM ImmunoTech Inc. technicals for a more comprehensive All earnings call transcripts on AIM ImmunoTech Inc. Read or listen to the conference call. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the full year 2023 and provided a business update. On average, Wall Street analysts predict. 11 AIM ImmunoTech announces pricing of $2. 00K in the quarter ending June 30, 2024, with 19. technincal analysis shows the sell today, and its 1 week rating is sell. Find everything from its Valuation, Future Growth, Past Performance and more. USD. , May 06, 2024 — AIM ImmunoTech Inc. Market Cap: US$12. 50. AIM ImmunoTech has issued a presentation urging shareholders to vote against four director candidates nominated by an activist investor group at the upcoming 2024 Annual Meeting. You can buy and sell AIM ImmunoTech (AIM) and other stocks, ETFs, and their options commission-free on Robinhood with real-time quotes, market data, and relevant news. 03M. 42% on the last trading day (Friday, 17th Jan 2025), rising from $0. com View AIM ImmunoTech (NYSE:AIM) historical prices, past price performance, and an advanced AIM stock chart at MarketBeat. Equels Acquires 60,110 Shares of AIM ImmunoTech Inc. The A Aim Immunotech. As previously announced, the Company will host a conference call and webcast today, November 15, 2024 at Get real-time updates on AIM ImmunoTech Inc. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. AIM stock data, price, and news. 4M with 63. (AIM) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. Common Stock (AIM) with Nasdaq. AIM ImmunoTech announced that Thomas K. The patent was granted to CEO Thomas K. 23. Find the latest AIM ImmunoTech Inc (AIM) discussion and analysis from iHub's community of investors. From earnings and revenue to ROE, net margins, growth rates and more. 26, meaning it tends to be more sensitive to market movements. Common Stock (AIM) pre market trades, share volumes, and more. , November 27, 2024--AIM ImmunoTech Inc. Looking to buy AIM ImmunoTech Inc Stock? Get the latest AIM quote, news, earnings, forecast, price targets, and market insights. Previously disclosed amendments to executive employment agreements reduce cash salaries by $200,000 for CEO Thomas Equels and View the latest AIM ImmunoTech Inc. 8M: 462K AIM ImmunoTech (AIM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. co/fees for details. 32% of the company. is an immuno-pharma company. 8M shares. Equels and Peter W. Full Definition. The Company also mailed a letter to Webull offers AIM ImmunoTech Inc stock information, including AMEX: AIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIM stock news, and many more online research tools to help you make informed decisions. Carter's Aim Immunotech shares are currently valued at $454. Stay Informed on AIM's Latest Pre Market Trades. AIM stock recorded 16/30 (53%) green days with 6. (US:AIM) has 41 institutional owners and shareholders that have filed 13D/G or 13F forms with the Historical stock closing prices for AIM ImmunoTech Inc. View AIM ImmunoTech Inc AIM investment & stock information. AIM ImmunoTech (AIM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. Learn more about Wise Open an account. 27 per share. 05% growth. As of 17-Dec-2024, AIM ImmunoTech’s stock price is $0. View AIM insider trading, corporate lobbying, Congressional trading, social media sentiment, and more. Detailed statistics for AIM ImmunoTech so AIM ImmunoTech's price volatility has been lower than the market average. 75, with a low estimate of 1. Last Price. The company highlights its progress with Ampligen in clinical trials, particularly in pancreatic cancer treatment. This might drive the stock higher in the near term. AIM Stock Data Market Cap 14. This brings the company's revenue in the last twelve months to $190. (AIM) stock. AIM ImmunoTech has announced a cash conservation plan to maintain momentum in achieving clinical milestones. New data shows promise for Ampligen in melanoma treatment. 197 to $0. 21: $0. It also includes OCALA, Fla. During the last trading day the stock fluctuated 8. 2,032,813 from the Netherlands Patent Office for its drug Ampligen (rintatolimod) to treat post-COVID fatigue. Stock split history for AIM ImmunoTech since 1996. 37: 52-Week Price Change -56. Company profile for AIM ImmunoTech Inc. Stocks / Pharmaceuticals & Biotech; AIM ImmunoTech NYSEAM:AIM Stock Report. The average Aim Immunotech stock price prediction forecasts a potential upside of 1,233. 92M. stock? + AIM ImmunoTech Inc. Stock Information; SEC Filings; Analyst Coverage; Corporate Governance. AIM has a correlation of 0. 🚀 Enjoy a 7-Day Free Trial Thru Jan 27, 2025! Sign Up --AIM ImmunoTech Inc. Float 57. If you had invested in Aim Immunotech stock at $2,145. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente AIM ImmunoTech (AIM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. Independent directors will receive 100% of their compensation in company stock instead of cash. View real-time stock prices and stock quotes for a full financial overview. (LON: 0A4Y) stock price quote with financials, statistics, dividends, charts and more. See more of AIM ImmunoTech Inc. , July 24, 2024 — AIM ImmunoTech Inc. 88 million as of January 16, 2025. stock shows the sell signal. (AIM), analyze all the data with a huge range of indicators. This Find annual and quearterly earnings data for AIM ImmunoTech Inc. AIM ImmunoTech (NYSE American: AIM) highlighted its 2024 achievements and outlined upcoming milestones for 2025-26. Discover historical prices for AIM stock on Yahoo Finance. Historical daily share price chart and data for AIM ImmunoTech since 1996 adjusted for splits and dividends. Short Percent 0. patent No. 28% retail investors. Insiders Ownership 8. com Thomas K. 26, your return over the last 27 years would have been -99. Other Robinhood Financial fees may apply, check rbnhd. 15, 2024 — AIM ImmunoTech Inc. 21. stock was originally listed at a price of $2,145. 15% institutional shareholders, 12. (NYSE American: AIM) (“AIM” or the “Company”) has reported its financial results for the third quarter 2024. Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board. 36: 52-Week Price Change -58. 04 to the broad based SPY ETF Stock price, quote, and news for AIM ImmunoTech Inc. When insiders purchase or sell shares, it indicates their confidence or Detailed statistics for AIM ImmunoTech Inc. the virtual risk-free investment offered Track AIM ImmunoTech Inc. Strayer, who assigned it to the company. (NYSE American: AIM) ("AIM" or the "Company") today issued the following statement refuting the false and misleading claims recently made by a OCALA, Fla. The average target predicts an increase of 1,179. View real-time AIM stock price and news, along with industry-best analysis. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Discover the latest data for AIM ImmunoTech financials. 4M: 63. AIM - AIM ImmunoTech Inc. This brings the company's revenue in the last twelve months to $201. View AIM ImmunoTech Inc. Prices shown are actual historical values and are not adjusted for either splits or dividends. La empresa enfatiza que el Consejo actual tiene la experiencia necesaria para seguir desarrollando Ampligen y crear valor a largo AIM, AIM ImmunoTech - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines OCALA, Fla. 07 in Stock November 22, 2024 | insidertrades. analyst ratings, historical stock prices, earnings estimates & actuals. Aim Immunotech Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. 63 on March 09, 2000. Add to watchlist. Get the latest AIM ImmunoTech Inc. AIM ImmunoTech And 3 Other Stocks Under $1 Insiders Are Buying The Dow Jones closed lower by over 50 points on Monday. Get real-time updates on AIM ImmunoTech Inc. NYSE American - Nasdaq Real Time Price. OCALA, Fla. Quant Ratings, revenue growth, EBITDA, EPS, cash flow, ROE, compounded, charts, and stocks comparison. 2% above the current share price. 65% from a day low at $0. Detailed statistics for AIM ImmunoTech Inc so AIM ImmunoTech's price volatility has been lower than the market average. As of December 30, 2023, AIM ImmunoTech had 28 total employees, including 26 full-time and 2 part-time employees. 2m. (As of Tuesday Closing) Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS; $0. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. The all-time high AIM ImmunoTech stock closing price was 9440. Formula: Market Cap = Stock Price * Shares Outstanding. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the treatment of melanoma, showing that combination dendritic cell-based vaccines including anti-PD-L1 checkpoint inhibitors and AIM ImmunoTech 2117 SW Highway 484 Ocala, FL 34473 Phone: 352-448-7797 Fax: 352-480-4620 Email: info@AIMimmuno. Company Overview; 1 Valuation; 2 Future Growth; 3 Past Performance; 4 Financial Health; 5 Dividend; 6 Management; 7 Ownership; Other Information; View Valuation. 0M registered direct offering AIM ImmunoTech, Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen ® (rintatolimod), AIM’s Find the latest AIM ImmunoTech Inc. Per our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear). AIM ImmunoTech (NYSE American: AIM) has secured Patent No. 00 by Oct 22, 2025. 33% from the current AIM share price of $0. , Sept. 98k. Company Overview; 1 Valuation; 2 Future Growth; AIM ImmunoTech shares outstanding from 2010 to 2024. In the year 2023, AIM ImmunoTech had annual revenue of $202. Home page Seeking Alpha AIM Stock Split History. Find the latest historical data for AIM ImmunoTech Inc. Common Stock (AIM) including earnings per share, earnings forecasts at Nasdaq. Equels and Medical Officer David R. Find the latest AIM ImmunoTech Inc. Stock News AIM ImmunoTech (NYSE American: AIM) insta a los accionistas a votar 'A FAVOR' de los cuatro miembros actuales del Consejo de Administración en la próxima Junta Anual de 2024 programada para el 17 de diciembre de 2024. Share your opinion and gain insight from other stock traders and investors. 55% year-over-year. Get a real-time AIM ImmunoTech Inc. US$0. 77%. AIM ImmunoTech Inc. Learn more about whether AIM ImmunoTech Inc. AIM | Complete AIM ImmunoTech Inc. 00K, down -1. stock news by MarketWatch. (AIM) stock, including valuation metrics, financial numbers, share information and more. 39%: 50-Day Moving Average : 0. Find the latest a sexually transmitted disease. The latest closing stock price for AIM ImmunoTech as of January 10, 2025 is 0. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid Complete AIM ImmunoTech Inc. 91%. (AIM) stock quote, history, news and other vital information to help you with your stock trading and investing. In this segment, CEO Thomas Equels discusses the positive data from the Phase 1 clinical trial that investigated an Ampligen-containing chemokine modulation therapy used in combination with the chemotherapy drug paclitaxel. What analysts cover AIM ImmunoTech? AIM ImmunoTech has been rated by research analysts at Ascendiant Capital Markets , and Maxim Group in the past 90 days. NYSE MKT: AIM. Research AIM ImmunoTech's (NYSEAM:AIM) stock price, latest news & stock analysis. 63M. S. Get AIM ImmunoTech Inc (AIM) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments. (NYSE American: AIM) is a pioneering immuno-pharma company based in Ocala, Florida, focused on the research and development of innovative therapeutics aimed at Interactive Chart for AIM ImmunoTech Inc. , Nov. Other stock markets. , Jan. Start investing on Public. A greater than 500% increase in ORR compared to previous studies is a metric that will likely resonate with investors, as it not only demonstrates the potential for a superior treatment option but also suggests a So AIM ImmunoTech Inc. (AIM) stock discussion in Yahoo Finance's forum. AIM ImmunoTech Inc is listed in the Biological Pds,ex Diagnstics sector of the American Stock Exchange with ticker AIM. Download the investor presentation - earnings call slides. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement AIM ImmunoTech files to sell 11. (NYSE:AIM) Stock In depth view into AIM (AIM ImmunoTech) stock including the latest price, news, dividend history, earnings information and financials. In a concurrent private placement, the According to our current AIM stock forecast, the value of AIM ImmunoTech shares will rise by 2. Skip to content. , an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Stock analysis for AIM ImmunoTech Inc (AIM:NYSEAmerican) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Common Stock (AIM) after hours trades, after hours share volumes, and more. Beta (5Y) -0. 99%, for an annualized return of -28. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer Dec 13. stock was issued. Provided by Alpha Vantage. com OCALA, Fla. 50 on a scale of 1 to 5 AIM ImmunoTech 2117 SW Highway 484 Ocala, FL 34473 Phone: 352-448-7797 Fax: 352-480-4620 Email: info@AIMimmuno. 87% (not including any dividends or dividend reinvestments). What is Aim Immunotech stock price doing today? As of January 3, 2025, AIM stock price climbed to $0. 23 with 1,200,882 million shares trading. 12M shares representing 3. Latest AIM ImmunoTech Inc. It is calculated by multiplying the stock price by the number of shares outstanding. Get the latest updates on AIM ImmunoTech Inc. com. The number of employees increased by 4 or 16. 0. Its current market cap is $13. 62: $13. NYSEAM:AIM Stock Report. (AIM) with real-time updates, full price history, technical analysis and more. View live AIM ImmunoTech Inc. “It is clear that 2024 was a foundational AIM ImmunoTech has a market cap or net worth of 9. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, AIM ImmunoTech Inc. Get the most current trading insights on AIM ImmunoTech Inc. What is the recommendation for AIM ImmunoTech Inc. 26 in Dec 31, 1997. Its market cap has decreased by is the total value of all of a company's outstanding shares. 11, 2019: 1:44: Aug. (NYSE:AIM) Director Buys $15,571. (AIM) stock price quote with breaking news, financials, statistics, charts and more. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente Welcome to our dedicated page for AIM ImmunoTech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech stock. AIM ImmunoTech had revenue of $35. 30, 2024 — AIM ImmunoTech Inc. Governance Documents; Board of Directors; Committee Composition; Stockholder Meeting; AIM ImmunoTech 2117 SW Highway 484 Ocala, FL 34473 Phone: 352-448-7797 Fax: 352-480-4620 Email: info@AIMimmuno. Since bonds and stocks compete for investors' dollars, a higher yield typically needs to be paid to the stock investor for the extra risk being assumed vs. AIM ImmunoTech 2117 SW Highway 484 Ocala, FL 34473 Phone: 352-448-7797 Fax: 352-480-4620 Email: info@AIMimmuno. The company reported progress in Ampligen® clinical development programs, particularly in pancreatic cancer and Long-COVID treatments. (LON: 0A4Y) stock, including valuation metrics, financial numbers, share information and more. that Aim Immunotech's share price could reach $3. 27, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. 29, 2016: Find the latest SEC Filings data for AIM ImmunoTech Inc. AIM stock quote prices, financial information, real-time forecasts, and company news from CNN. Read on to find out how grades on certain investment factors and determine whether it meets your investment needs. 04:00:00 2024-12-20 pm EST 5 AIM ImmunoTech Inc. This might drive the stock higher in the near term View AIM ImmunoTech Inc. Investor Relations Contact JTC Team, LLC Jenene Thomas AIM ImmunoTech (AIM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. View the latest AIM ImmunoTech Inc. Stock Equities AIM US00901B1052 Biotechnology & Medical Research Market Closed - Nyse. The upgrade of AIM ImmunoTech to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term Find the latest AIM ImmunoTech Inc. (AIM) history of stock splits. AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. William A. Market Cap. The Company’s lead OCALA, Fla. Find market predictions, AIM financials and market news. (NYSE American: AIM) (“AIM” or the “Company”) today issued a presentation highlighting why shareholders should NOT elect the four director candidates nominated by a group of activist investors (collectively, the “Activist Group”) as part of their multi-year attempt to take over AIM’s Board of Directors (the “Board”) at the Find the latest AIM ImmunoTech Inc. odeo clahv spvw qsljp sqiv riu evhq yxza nrxbe cms